NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

INTERVENTIONAL PROCEDURES PROGRAMME

Equality impact assessment

IPG768 Irreversible electroporation for treating prostate cancer

The impact on equality has been assessed during guidance development according to the principles of the NICE Equality scheme.

Briefing

1. Have any potential equality issues been identified during the briefing process (development of the brief or discussion at the committee meeting), and, if so, what are they?

Disability: All people with cancer are covered by the disability provision of the Equality Act 2010 from the point of diagnosis.

Age: The chance of developing prostate cancer increases with age. Most cases develop in men aged 70 or older.

Ethnicity: Prostate cancer is more common in men of African-Caribbean or African descent, and less common in men of Asian descent.

Socioeconomic status: There is a higher incidence of prostate cancer in the less socio-economically deprived areas, which is assumed to be due to higher rates of prostate specific antigen testing among affluent men.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee? (If there are exclusions listed in the brief (for example, populations, treatments or settings), are these justified?)

This was not thought to have an impact on the assessment of the procedure. No exclusions were applied.

3.	Has any change to the brief (such as additional issues raised during the committee meeting) been agreed to highlight potential equality issues?
No	
4.	Have any additional stakeholders related to potential equality issues been identified during the committee meeting, and, if so, have changes to the stakeholder list been made?'
No	
	13/05/2023 ultation
Cons	ultation Have the potential equality issues identified during the briefing
	process been addressed by the committee, and, if so, how?
The key evidence reviewed by the committee included patients with a median age from 63 to 72 years.	
No specific data relating to other issues mentioned earlier was identified in the literature presented in the overview.	
2.	Have any other potential equality issues been raised in the overview, specialist adviser questionnaires or patient commentary, and, if so, how has the committee addressed these?
No	


3.	Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?	
No		
4.	Do the preliminary recommendations make it more difficult in practice for a specific group to access a technology or intervention compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?	
No		
5.	Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?	
Not applicable		
6.	Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligation to promote equality?	
Not applicable		
7.	Have the committee's considerations of equality issues been described in the consultation document, and, if so, where?	
No		

Chris Chesters

Approved by Senior Health Technology Assessment Advisor

Date: 13/05/2023

Final interventional procedures document



2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access a technology or intervention compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

Not applicable

3. If the recommendations have changed after consultation, is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

Not applicable

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

Not applicable

5. Have the committee's considerations of equality issues been described in the final interventional procedures document, and, if so, where?
No

Anastasia Chalkidou

Associate Director

Date: 11/05/2023